Gilead Gets Wall Street Love After Q2 Earnings Beat

By | July 29, 2015

Scalper1 News

Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and the increased guidance, from a company known for conservative forecasting. Piper Jaffray analyst Joshua Schimmer raised his price target on Gilead stock to 134 from 131 based on the news. “While the Scalper1 News

Scalper1 News